Academic psychiatry and the pharmaceutical industry

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 3, 2006, Pages 429-441

  Ban, Thomas A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Academic psychiatry; Antidepressants; Antipsychotics; Composite Diagnostic Evaluation; Education; Marketing; Neuropharmacology; Neuropsychopharmacology; Nosologic matrix; Pharmaceutical industry; Psychiatric nosology; Psychopathology; Psychopharmacology

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; CHLORAL HYDRATE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DEXAMPHETAMINE; LEVOMEPROMAZINE; MORPHINE; NICOTINIC ACID; PARALDEHYDE; PENICILLIN G; PERPHENAZINE; PHENYTOIN; POTASSIUM BROMIDE; PROCHLORPERAZINE; RESERPINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; THIAMINE; THIOPROPAZATE; THIOPROPERAZINE; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG;

ACETYLCHOLINE RELEASE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; AMNESIA; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR CONTROL; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BRAIN TOXICITY; CARDIOMYOPATHY; CONVULSIVE THERAPY; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG FATALITY; DRUG FEVER; DRUG INDUSTRY; ENDOGENOUS PSYCHOSIS; EPILEPSY; EXCITEMENT; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEART INJURY; HEART MUSCLE CONDUCTION DISTURBANCE; HISTORY OF MEDICINE; HUMAN; INSOMNIA; INTESTINAL DYSMOTILITY; MANIA; MOOD CHANGE; MYOCARDITIS; NARCOLEPSY; NEUROPHARMACOLOGY; NEUROSIS; NEUROSYPHILIS; PELLAGRA; PHYSIOTHERAPIST; PICK PRESENILE DEMENTIA; PSYCHIATRY; PSYCHOSIS; RESTLESSNESS; RETINOPATHY; REVIEW; SCHIZOPHRENIA; SEIZURE; SENILE DEMENTIA; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SLEEP INDUCTION; SUICIDAL BEHAVIOR; TENSION; WERNICKE ENCEPHALOPATHY;

ACADEMIES AND INSTITUTES; DRUG INDUSTRY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEUROPHARMACOLOGY; PSYCHIATRY; PSYCHOPHARMACOLOGY; RESEARCH;

EID: 33646018911     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.014     Document Type: Review

References (156)

1. Ackenheil M., and Hippius H. Clozapine. In: Usdin E., and Forrest I. (Eds). Psychotherapeutic drugs. Applications vol. 2 (1977), Marcel Dekker, Inc., New York 923-956 (Section 4, Chapter 6)
2. American Psychiatric Association. Diagnostic and statistical manual. Third Edition (1980), American Psychiatric Association, Washington, DC
3. American Psychiatric Association. Diagnostic and statistical manual. Third Edition (1994), American Psychiatric Association, Washington, DC
4. Angst J., Battegay R., Bente D., Berner P., Broeren W., Cornu F., et al. The documentation system of the Association for Methodology and Documentation in Psychiatry (AMP). Arzneim Forsch 19 (1969) 399-405
5. Angst J., Bente D., Berner P., Heimann H., Helmchen H., and Hippius H. The clinical efficacy of clozapine. (Investigation with the AMP System). Neuropsychopharmacology 4 (1971) 201-211
6. Asberg M., Perris C., Schalling D., and Sedvall G. The CPRS-development and application of a psychiatric rating scale. Acta Psychiatr Scand Suppl. 271 (1978)
7. Astrup C. The effects of ataraxic drugs on schizophrenic subgroups related to experimental findings. Acta Psychiatr Scand 34 Suppl. 136 (1959) S388-S393
8. 3H-norepinephrine by tissues. Science 133 (1961) 383-384
9. Ban T.A. Psychopharmacology (1969), Williams & Wilkins, Baltimore (MD)
10. Ban T.A. Depression and the tricyclic antidepressants (1974), Ronalds Federated, Montreal
11. Ban T.A. Psychopharmacology of depression. A guide for drug treatment (1981), S. Karger, Basle
12. Ban T.A. Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 11 (1987) 527-580
13. Ban T.A. CODE-DD Composite Diagnostic Evaluation in Depressive Disorders (1989), JM Productions, Nashville (TN)
14. Ban T.A. CODE System: theory and practice. In: Aguglia E., and Ban T.A. (Eds). International symposium on functional psychoses today (1991), John Libbey, Rome 279-296
15. Ban T.A. The CODE System in psychiatric research. Pharmacoecopsychologia 4 (1991) 41-49
16. Ban T.A. Composite diagnostic evaluation: methodology and applications. In: Ferrero F.P., Haynal A.E., and Sartorius N. (Eds). Schizophrenia and affective psychoses. Nosology in contemporary psychiatry (1992), John Libbey, Rome 410-419
17. Ban T.A. They used to call it psychiatry. In: Healy D. (Ed). The Psychopharmacologists, Altman (1996), Chapman and Hall, London 587-620 (Interviews, Chapter 25)
18. Ban T.A. Nosology in the teaching of psychiatry. J Bras Psiquiatr 49 (2000) 39-49
19. Ban T.A. Pharmacotherapy of depression: a historical analysis. J Neurol Transm 108 (2001) 707-711
20. Ban T.A. Pharmacotherapy of mental illness: a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry 28 (2001) 709-727
21. Ban T.A. The CODE system in psychiatry. Neuropsychopharmacol Hung 3 (2001) 6-10
22. Ban T.A. Neuropsychopharmacology: the interface between the genes and psychiatric nosology. In: Lerer B. (Ed). Pharmacogenetics of psychotropic drugs (2002), Cambridge University Press, Cambridge, UK 36-56
23. Ban T.A. Neuropsychopharmacology and the history of pharmacotherapy in psychiatry. a review of developments in the 20th century. In: Ban T.A., Healy D., and Shorter E. (Eds). Reflections on twentieth-century psychopharmacology (2004), Animula, Budapest 697-720
24. Ban T.A., and St. Jean A. The effect of phenothiazines on the electrocardiogram. Can Med Assoc J 91 (1964) 537-540
25. Ban T.A., Fjetland O.K., Kutscher M., and Morey L.C. CODE-DD: development of a diagnostic scale for depressive disorders. In: Hindmarch I., and Stonier P.D. (Eds). Human psychopharmacology. Measures and Methods vol. 4 (1993), John Wiley & Sons, Chichester 73-85 Chapter 5
26. Ban A., Gaszner P., Aguglia E., Batista R., Castillo A., Lipcsey A., et al. Clinical efficacy of reboxetine. A comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 13 (1998) S29-S39
27. Bayle A.L.J. Traité des Maladies du Cerveau et de ses Membranes (1826), Gabon, Paris
28. Beard G.M. Neurasthenia or nervous exhaustion. Boston Med Surg J 3 (1869) 217-218
29. Benedikt P. Über Platzschwindel. Allgemeine Wiener medizinische Zeitung 15 (1870) 488-495
30. Berner P., Gabriel F., Katschnig H., Kieffer W., Koehler K., Lenz G., et al. Diagnostic criteria for schizophrenic and affective psychoses (1983), World Psychiatric Association and American Psychiatric Association, Washington, DC
31. Besendorf H., and Pletscher A. Beeinflussung zentraler Wirkungen von Reserpin und 5-hydroxytryptamin durch Isonicotinic-säuerhydrazine. Helv Physiol Acta 14 (1956) 383-390
32. Bonhoeffer K. Zur Frage der exogenen Psychosen. Neur Zbl 32 (1909) 499-505
33. Bowman R.L., Caulfield P.A., and Udenfriend S. Spectrophotometric assay in the visible and ultraviolet. Science 122 (1955) 32-33
34. Bradley C.B. The behavior of children receiving benzedrine. Am J Psychiatry 94 (1937) 577-580
35. Briquet P. Traité clinique et thérapeutique à l' hystérie (1859), J.-B. Ballière & Fils, Paris
36. Brodie B.B., Shore P.A., and Pletscher A. Limitations of serotonin releasing activity to those Rauwolfia alkaloids possessing tranquilizing action. Science 123 (1956) 992-993
37. Brodie B.B., Bickel H., and Sulser F. Desmethylimipramine, a new type of antidepressant drug. Med Exp 5 (1961) 454-458
38. Bunney Jr. W.E., and Davis J.M. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 13 (1965) 483-494
39. 3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 12 (1976) 800-812
40. Cade J.F. Lithium salts in the treatment of psychotic excitement. Med J Aust 2 (1949) 349-352
41. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine on mouse brain. Acta Pharmacol Toxicol 20 (1963) 140-144
42. Cerletti U., and Bini L. L'Ellettroshock. Arch Gen Neurol 19 (1938) 266-268
43. Cervello V. Über die Physiologische Wirkung des Paraldehyds und Beiträge zu den Studien über das Chloral-hydrate. Arch Exp Path Pharmacol 16 (1882) 265-290
44. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59 (1998) 352-357
45. Costa E., Garattini S., and Valzelli L. Interaction between reserpine, chlorpromazine and imipramine. Experientia 15 (1960) 461-463
46. CPS. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals (2004), Canadian Pharmacists Association, Ottawa
47. De Wardener H.E., and Lennox B. Cerebral beri-beri (Wernicke's encephalopathy): review of 52 cases in Singapore prisoner-of-war hospital. Lancet 1 (1947) 11-17
48. Edeleano L. Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure. Berl Dtsch Chem Ges 20 (1887) 616-620
49. Elvehjem C.A., Madden R.J., Strong F.M., and Wooley D.W. The isolation and the identification of the anti-blacktongue factor. J Biol Chem 123 (1937) 137-149
50. Encyclopedia Britannica. University. Encyclopedia Britannica vol. 22 (1969), William Benton Publisher, Chicago (IL) 745-766
51. Encyclopedia Britannica. Atoms. Encyclopedia Britannica vol. 2 (1969), William Benton Publisher, Chicago (IL) 794-796
52. Esquirol J.E.D. Des maladies mentales considérées sous les rapports médical, hygiénique et médico-légal (1838), J.P. Baillière, Paris
53. Falret J.P.P. De la Folie Circulaire. Bull Acad Med (Paris) 19 (1854) 382-400
54. Feuchtersleben E. Lehrbuch der Ärztlichen Seelenkunde (1845), Carl Gerold, Vienna
55. Fish F. The influence of the tranquilizer on the Leonhard schizophrenic syndromes. Encephale 53 (1964) 245-249
56. Flaherty J.A. The psychiatric use of isonicotinic acid hydrazide: a case report. Del Med J 24 (1952) 298-300
57. Fleming A. On the antibacterial action of cultures of penicillium with special reference to their use in the isolation of B. influensae. Br J Exp Pathol 10 (1929) 226-236
58. Fouts P.J., Helmer O.M., Lepkovsky Y.S., and Jukes T.H. Treatment of human pellagra with nicotinic acid. Proc Soc Exp Biol Med 37 (1937) 405-407
59. Franzek E. Influence of Carl Wernicke on Karl Leonhard's nosology. Psychopathology 23 (1990) 277-281
60. Freyhan F. Selection of patients from the clinical point of view. In: Cole J.O., and Gerard R.W. (Eds). Psychopharmacology Problems in Evaluation. (Proceedings of a Conference on The Evaluation of Pharmacotherapy in Mental Illness, sponsored by the National Institute of Mental Health, the National Academy of Sciences-National Research Council, and the American Psychiatric Association, Washington, D.C. September 18-22, 1956) (1959), National Academy of Sciences, National Research Council, Washington, DC 372-389
61. Freyhan F. The influence of specific and non-specific factors on the clinical effects of psychotropic drugs. In: Rothlin E. (Ed). Neuropsychopharmacology vol. 2 (1961), Elsevier, Amsterdam 189-203
62. Gardener D.M., Baldessarini R.J., and Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172 (2005) 1703-1711
63. Garrison F.H. History of Medicine (1960), Saunders, Philadelphia 682
64. Gerard R.W. Drugs for the soul: the rise of psychopharmacology. Science 125 (1957) 201-203
65. Gillespie R.D. The clinical differentiation of types of depression. Guy Hosp Rep 79 (1929) 306-344
66. Golgi C. In: Garrison, FH, editor. History of Medicine. W.B. Saunders Company: Philadelphia, PA., 1873. p. 525. 1960.
67. Golgi, C. In: Garrison, FH, editor. History of Medicine. W.B. Saunders Company: Philadelphia, PA, 1883. p. 525. 1960.
68. Guy W. ECDEU Assessment Manual for Psychopharmacology-Publ. No. (ADM). (DHEW No. 76-338), Rockville, National Institute of Mental Health) (1976), United States Government Printing Office, Washington, DC
69. In: Guy W., and Ban T.A. (Eds). The AMDP-System. Manual for the assessment and documentation in psychopathology (1982), Springer, Berlin
70. Gyermek L., Lázár G.T., and Csák Zs. The antiserotonin action of chlorpromazine and some other phenothiazine derivatives. Arch Int Pharmacodyn 107 (1956) 62-74
71. Healy D. The antidepressant era (1997), Harvard Univ. Press, Cambridge, MA, USA 15-21-24-28 166, 288, 291
72. Healy D. The creation of psychopharmacology (2002), Harvard Univ. Press, Cambridge, MA 34-35
73. Healy D. Let them eat Prozac (2003), James Lorimer and Company Ltd, Toronto
74. Hecker E. Die Hebephrenie. Arch Pathol Anat Physiol Klin Med 52 (1871) 394-409
75. Huff D. How to lie with statistics (1954), W.W. Norton and Company, New York 1
76. Idanpaan-Hikkila J., Alhava E., Olkimora M., and Palva J. Clozapine in agranulocytosis. Lancet (1975 (Sept 27)) 611
77. Jansen B.C.P., and Donath W.F. Vitamins. Encyclopedia Britannica vol. 23 (1926), Wiliam Benton Publishers, Chicago 84-88
78. Janssen P., Niemegeers C.J.E., and Schellekens K.H.L. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I. Neuroleptic activity spectra for rats. Arzneimittelforschung 15 (1965) 104-117
79. Jaspers K. Eifersuchtswahn: Entwicklung einer Persönlichkeit oder Prozess. Z Ges Neurol Psychiatr 1 (1910) 567-637
80. Jaspers K. Allgemeine psychopathologie (1913), Springer, Berlin
81. Kahlbaum K.L. Die Katatonie oder das Spannungsirresein (1874), Hirschwald, Berlin
82. Kane J., Honigfeld G., Singer J., and Meltzer H.Y. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (1988) 789-796
83. Kelley M.R., Fay J.E., and Laverty S.G. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report on two fatalities with electrocardiographic abnormalities. J Can Med Assoc J 89 (1963) 546-554
84. Kennedy S.H., Lam R.W., Cohen N.L., and Ravindran A.V. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46 Suppl. 1 (2001) 38S-58S
85. Kirsch I., Moore T.J., Scoboria A., and Nicholls S.S. The emperor's new drugs: An analysis of antidepressant data submitted to the US Food and Drug Administration. Prev. Treat. 5 (2002). http://journals.apa.org/prevention/volume5/pre0050023a.html (Page 23, Article A, posted July 15, 2002. http://journals.apa.org/prevention/volume5/pre0050023a.html. Quoted in Szendi, G., 2004. A depresszioipar. Mozgo Vilag 10, 9-30, p. 18)
86. Kirsch I., Scoboria A., and Moore T.J. Antidepressants and placebos: secrets, revelations, and unanswered questions. Prev. Treat. 5 (2002). http://journals.apa.org/prevention/volume5/pre0050033r.html (Page 33, Article R, posted July 15, 2002. http://journals.apa.org/prevention/volume5/pre0050033r.html. Quoted in: Szendi, G., 2004. A depresszioipar. Mozgo Vilag 10, 9-30, p. 19)
87. Kleist K. Die Aufteilung der Schizophrenien als Systemkrankheiten. Klin J Wochenschr 2 (1923) 962-965
88. Kline N.S. Psychiatric diagnosis and typology of clinical drug effects. Psychopharmacologia 13 (1968) 359-386
89. Kline D.F., and Davis J. Diagnosis and drug treatment of psychiatric disorders (1969), Williams and Wilkins, Baltimore
90. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6 (1899), Auflage, Barth, Lepzig
91. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte, 8 Auflage, Barth, Leipzig; 1910 (1908-1913).
92. Kraepelin E. Manic-Depressive Insanity and Paranoia. (Translated from German into English by Barclay, M. B.) (1921), Livingstone, Edinburgh
93. Krafft-Ebing R. Lehrbuch der Psychiatrie (1872), Enke, Stuttgart
94. Kuhn R. Über die Behandlung depressives Zustande mit einem iminodibenzyl-derivat (G22355). Schweiz Med Wochenschr 87 (1957) 1135-1140
95. Lam R.W., and Kennedy S.H. Prescribing antidepressants for depression in 2005: recent concerns and recommendations. Can J Psychiatry 49 (2005) 1-6 [Insert 12]
96. Lambert P.-A., Perrin J., Revol L., Achaintre P., Balvet A., Beaujard M., et al. Essai de classification des neuroleptiques d'apres leurs activites psycho-pharmacologiques et cliniques. In: Bradley P.B., Deniker P., and Radouco-Thomas C. (Eds). Neuropsychopharmacology (1959), Elsevier, Amsterdam 619-624
97. 3H-imipramine binding in the rat hypothalamus. Association with uptake of serotonin, but not of norepinephrine. Science 210 (1980) 1133-1135
98. Lasègue E.C. Du déire de persecution. Arch Gen Med 28 (1852) 129-150
99. In: Lehmann H.E., and Ban T.A. (Eds). Toxicity and adverse reaction studies with neuroleptics and antidepressants. Skin-eye syndrome and electrocardiographic changes (1965), Quebec Psychopharmacological Research Association, Montreal
100. Lehmann H.E., and Ban T.A. Pharmacotherapy of tension and anxiety (1970), Charles C. Thomas, Springfield, Ill. 14-15
101. Lehmann H.E., and Ban T.A. The history of the psychopharmacology of schizophrenia. Can J Psychiatry 42 (1997) 152-162
102. Lemmens T. Confronting the conflict of interest crisis in medical research. Monash Bioeth Rev 23 (2004) 19-40
103. Leonhard K. Aufteilung der endogenen Psychosen (1957), Akademie-Verlag, Berlin
104. Lewis A. Melancholia. A clinical survey of depressive states. Journal of Mental Science 80 (1934) 277-378
105. Liebreich M.E.P. Das chloral hydrate, ein neues Hypnoticum und Anaestheticum, und dessen Anwendung in der Medizin (1869), Eine Arzneimittel-Untersuchung, Berlin, Müller
106. Liepmann H.K. Drei Aufsätze aus dem Apraxiegebret (1908), Karger, Berlin
107. Loewi O. Über die Beziehungen zwischen Herzmittel und physiologischer Kationenwirkung. VI. Über de Kaliumcontractur. Arch Physiol 138 (1921) 87-97 [Berlin]
108. Macht D.L. Contributions to psychopharmacology. Bull Hopkins Hosp 31 (1920) 167-173
109. Marshall B. Manufacturing distress: sexual dysfunction and the politics of disease-control. Presented at a symposium (hosted by The History of Medicine Program, Faculty of Medicine, University of Toronto, and sponsored by Associated Medical Services Inc., CIHR and Glaxo Smith Kline) on The Social Sources of Psychopharmacology Part II The Univerrsity in Crisis, on April 28-29, 2005, in Toronto, Ontario, Canada (2005)
110. Mayer-Gross W., Slater E., and Roth M. Clinical Psychiatry. Second edition (1960), Cassell and Corporation, London 486
111. Meduna L. Die Konvulsiontherapie der Schizophrenie (1937), Marhold, Halle
112. Möbius J.P. Abriss der Lehre von den Nervenkrankheiten (1893), Leipzig
113. Moreau de Tours J. Du Hachich et de L'Aliénation Mentale. Etudes Psychologiques (1845), Fortin Masson, Paris
114. Morel B-A. Etude-Cliniques. Tom I-II, Baillière, Paris. 1852-1853.
115. Morel B.-A. Traité des Maladies Mentales (1860), Mason, Paris
116. Morel B-A. Archives générales de médicine. In: Shorter E, editor. A Historical Dictionary of Psychiatry. Oxford University Press: Oxford, England, 1866 p. 27. 2005
117. Oppenheim H. Quoted after Kraepelin 1896 by Jablensky, S., Approaches to the definition and classification of anxiety and related disorders in European Psychiatry. In: Tuma AH, JD Maser JD, (editors). Anxiety and the anxiety disorders, Lawrence Erlbaum Associates Publishers: Hillsdale, NJ.; 1892. pp. 735-758. 1985.
118. Paul S., Rehavi M., Skolnick P., and Goodwin F.K. Demonstration of high affinity binding sites for [3-H] imipramine in human platelets. Life Sci 26 (1980) 953-959
119. Petho B. Development and structure of the DCR Budapest-Nashville. Psychopathology 23 316 (1990) 316-330
120. Pichot P. A Century of Psychiatry (1983), Roger Dacosta, Paris 57
121. Pick A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prag Med Wochenschr 17 (1892) 165-167
122. Pletscher A., Shore P.A., and Brodie B.B. Serotonin release as possible mechanism of reserpine action. Science 122 (1955) 374-375
123. Pletscher A., Shore P.A., and Brodie B.B. Serotonin as a modulator of reserpine action in brain. J Pharmacol Exp Ther 116 (1956) 84-89
124. Prinzmetal M., and Blumberg W. The use of benzedrine in the treatment of narcolepsy. JAMA 105 (1935) 2051-2053
125. Putnam T.J. The demonstration of the specific anticonvulsant action of diphenylhydantoin and related compounds. In: Ayd F.J., and Blackwell B. (Eds). Discoveries in biological psychiatry (1970), J. B. Lipponcott Company, Philadelphia 85-90
126. Quastel J.H., Tennenbaum M., and Wheatley A.H. Choline ester formation and choline esterase activities in tissues in vitro. Biochem J 30 (1936) 1068-1170
127. Reil JC. Über den Begriff der Medicin und ihre Verzweigungen, besonders in Beziechung auf die Berechtigung der Topik der Psychiaterie. In: Shorter, E., A Historical Dictionary of Psychiatry. Oxford University Press: Oxford; 1808. pp. 232-233. 2005.
128. Sakel M. Neue behandlung der Schizophrenie (1935), Perles, Vienna
129. Scharfetter C. The AMP system (1971), Springer, New York
130. Schneider K. Die Schichtung des emotionalen Lebens und der Aufbau der Depressionszustände. Z Ges Neurol Psychiatr 59 (1920) 281-285
131. Schneider K. Klinische Psychopathologie. 3 (1950), Auflage, Thieme, Stuttgart
132. Sechenov IM. Refleksy Golovnogo. St.Petersburg. In: Wells HK, edition. Ivan P Pavlov. International Publishers. New York; 1863. pp. 26-27. 1956.
133. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 261 (1975) 717-719
134. Seeman P., Lee T., Chau-Wong M., and Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976) 717-719
135. Selikoff I.J., Robitzek E.H., and Orenstein G.G. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA 150 (1952) 973-987
136. Sherrington C. In: Foster M, editor. Textbook of Physiology. Quoted by Shorter, E., 2005. A Historical Dictionary of Psychiatry. Oxford University Press; 1897. Oxford, p. 288.
137. Shorter E. A history of psychiatry (1997), John Wiley and Sons, Inc., New York 71-81
138. Shorter E. A historical dictionary of psychiatry (2005), Oxford Univ. Press, Oxford 288
139. Snyder S. The dopamine hypothesis of schizophrenia. Focus on the dopamine receptor. Am J Psychiatry 133 (1976) 140-144
140. Snyder S.H., Creese I., and Burt D.R. The brain's dopamine receptor: labeling with [3H] dopamine and [3H] haloperidol. Psychopharmacol Commun 1 (1975) 663-673
141. Stedman E., and Stedman F. Mechanism of biological synthesis of acetylcholine: isolation of acetylcholine produced by brain tissue in vitro. Biochem J 31 (1937) 817-820
142. Stokes J.H., Sternberg T.H., Schwartz W.H., Mahoney J.F., Moore J.E., and Wood W.B. The action of penicillin in late syphilis including neurosyphilis. JAMA 126 (1944) 73-79
143. Sulser F., Watts J., and Brodie B.B. On the mechanism of antidepressant action of imipramine-like drugs. Ann N Y Acad Sci 96 (1961) 270-296
144. Szendi G. A depresszioipar. (The depression-industry). Mozgo Vilag 10 (2004) 9-30
145. Thase M., Entsuah A., and Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin re-uptake inhibitors. Br J Psychiatry 178 (2001) 234-241
146. Usdin E., and Efron D.H. Psychotropic drugs and related compounds (1967), US Government Printing Office, Washington, DC
147. Van Rossum J.M. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H., Cole J.O., Deniker P., Hippius H., and Bradley P.B. (Eds). Neuropsychopharmacology. Proceedings of the fifth international congress of the collegium internationale neuro-psychopharmacologicum. (March 1966) (1967), Excerpta Medica Foundation, Amsterdam 321-329
148. Vetulani J., Stawarz R., Pringell J., and Sulser F. A possible common mechanism of antidepressant effect. NS Arch Pharmacol 243 (1975) 109-111
149. von Baeyer A. Untersuchungen über die Hernsäueregrouppe. Justus Liebigs Ann Chem Pharm 127 (1863) 1-27
150. Wernicke C. Lehrbuch der Gehirnkrankheiten, Schlettersche Buchhandlung, Breslau 1881.
151. Wernicke C. Über die Klassifikation der Psychosen. Schlettersche Buchhandlung, Breslau 1899.
152. Wernicke C. Grundrisse der Psychiatrie (1900), Thieme, Leipzig
153. Westen D., and Morrison K. A multidimensional meta-analysis of treatment for depression, panic, generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 69 (2001) 875-899
154. Westphal C. Über Zwangsvorstellungen. Arch. Psychiatr. Nervenkr. 8 (1878) 734-750
155. Wimmer A. Psykogene Syndssygdomsformer (1916), Lunds, Copenhagen
156. Wood A. A new method of treating neuralgia by the direct application of opiates to the painful points, Edinb. Med. and Surg. J. 82, 265-281. In: Shorter E, A History of Psychiatry. John Wiley and Sons: New York; 1855. p. 380. 2005.